title: LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin.
abstract: Human podoplanin (hPDPN), the ligand of C-type lectin-like receptor-2, is involved in cancer metastasis. Until now, many monoclonal antibodies (mAbs) have been established against hPDPN. However, it is still difficult to develop a cancer-specific mAb (CasMab) against hPDPN because the protein sequence of hPDPN expressed in cancer cells is the same as that in normal cells. Herein, we report LpMab-23 of the mouse IgG1subclass, a novel CasMab against hPDPN. In an immunohistochemical analysis, LpMab-23 reacted with tumor cells of human oral cancer, but did not react with normal cells such as lymphatic endothelial cells (LECs). In contrast, LpMab-17, another anti-hPDPN mAb, reacted with both tumor cells and LECs. Furthermore, flow cytometric analysis revealed that LpMab-23 reacted with hPDPN-expressing cancer cell lines (LN319, RERF-LC-AI/hPDPN, Y-MESO-14/hPDPN, and HSC3/hPDPN) but showed little reaction with normal cells (LECs and HEK-293T), although another anti-hPDPN mAb, LpMab-7, reacted with both hPDPN-expressing cancer cells and normal cells, indicating that LpMab-23 is a CasMab against hPDPN.
authors.affiliation: 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .|2 Department of Regional Innovation, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .
authors.forename: Shinji
authors.initials: S
authors.lastname: Yamada
authors.affiliation: 2 Department of Regional Innovation, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ogasawara
authors.affiliation: 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .|2 Department of Regional Innovation, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .
authors.forename: Mika K
authors.initials: MK
authors.lastname: Kaneko
authors.affiliation: 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .|2 Department of Regional Innovation, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .|3 New Industry Creation Hatchery Center, Tohoku University, Sendai, Miyagi, Japan .
authors.forename: Yukinari
authors.initials: Y
authors.lastname: Kato
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000737:chemistry* / Q000302:isolation & purification*; D000915:Antibody Affinity; D000918:Antibody Specificity; D002460:Cell Line; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D015870:Gene Expression; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007117:Immunization, Secondary / Q000379:methods*; D008562:Membrane Glycoproteins / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009928:Organ Specificity; D013154:Spleen / Q000166:cytology / Q000276:immunology; D000098853:Podoplanin
chemical_list: D000911:Antibodies, Monoclonal; D008562:Membrane Glycoproteins; C117468:PDPN protein, human; D000098853:Podoplanin
keywords: CasMab; cancer-specific antibody; monoclonal antibody; podoplanin